Department of Bionano Technology, Gachon Bionano Research Institute, Gachon University, 1342 Sungnam-daero, Seongnam-si, Gyeonggi-do 461-701, South Korea.
Department of Bionano Technology, Gachon Bionano Research Institute, Gachon University, 1342 Sungnam-daero, Seongnam-si, Gyeonggi-do 461-701, South Korea.
J Neurol Sci. 2018 Dec 15;395:62-70. doi: 10.1016/j.jns.2018.09.033. Epub 2018 Sep 28.
Alzheimer's Disease (AD) is one of the most common age-related neurodegenerative diseases in the developed world. Treatment of AD is particularly challenging as the drug must overcome the blood brain barrier (BBB) before it can reach its target. Mitochondria are recognized as one of the most important targets for neurological drugs as the organelle is known to play a critical role in diverse cellular processes such as energy production and apoptosis regulation. Mitochondrial targeting was originally developed to study mitochondrial dysfunction and the organelles interaction with other sub-cellular organelles. The purpose of this review is to provide an overview of mitochondrial dysfunction and its role in late onset AD pathology. We then highlight recent antioxidant and enzymatic treatments used to alleviate mitochondrial dysfunction. Finally, we describe current applications of targeted mitochondrial delivery in the treatment of AD.
阿尔茨海默病（AD）是发达国家最常见的与年龄相关的神经退行性疾病之一。AD 的治疗特别具有挑战性，因为药物必须克服血脑屏障（BBB）才能到达其靶标。线粒体被认为是神经药物的最重要靶点之一，因为该细胞器已知在多种细胞过程中发挥关键作用，如能量产生和细胞凋亡调节。线粒体靶向最初是为了研究线粒体功能障碍及其与其他亚细胞细胞器的相互作用而开发的。本综述的目的是概述线粒体功能障碍及其在迟发性 AD 发病机制中的作用。然后，我们强调了最近用于缓解线粒体功能障碍的抗氧化和酶治疗方法。最后，我们描述了靶向线粒体传递在 AD 治疗中的当前应用。
